Eluvia Drug-Eluting Vascular Stent System
Boston Scientific Corp · Decision date Oct 24, 2025
What did the FDA decide?
FDA records P180011/S067 as a supplement to PMA P180011, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 24, 2025.
FDA approval order statement
to reduce the number of rinse strokes in the electropolishing process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 24, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P180011/S067
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- NIU
- Decision code
- OK30
- Decision date
- Oct 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, superficial femoral artery, drug-eluting.
- Applicant
- Boston Scientific Corp
- Product code
- NIU
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180011/S066 · Related supplement
Eluvia Drug-Eluting Vascular Stent System
P180011/S067 received
Application receipt date recorded by FDA.
P180011/S067 · FDA decision
30-Day Notice
P180011/S060 · Related supplement
Eluvia Drug-Eluting Vascular Stent System
P180011/S069 · Related supplement
Eluvia Drug-Eluting Vascular Stent System
P180011/S070 · Related supplement
ELUVIA Drug-Eluting Vascular Stent System
Timeline entries are records held by MedtechLedger for P180011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Eluvia Drug-Eluting Vascular Stent SystemP180011/S066 | Boston Scientific Corp | PMA supplement | Aug 8, 2025 | FDA |
Eluvia Drug-Eluting Vascular Stent SystemP180011/S060 | Boston Scientific Corp | PMA supplement | Jan 30, 2026 | FDA |
Eluvia Drug-Eluting Vascular Stent SystemP180011/S069 | Boston Scientific Corp | PMA supplement | Aug 6, 2026 | FDA |
ELUVIA Drug-Eluting Vascular Stent SystemP180011/S070 | Boston Scientific Corp | PMA supplement | Aug 21, 2026 | FDA |
Explore the linked device profile
Other records with product code NIU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Zilver PTX Drug-Eluting Peripheral StentP100022/S046 | Cook Ireland, Ltd. | PMA supplement | Nov 6, 2026 | FDA |
Zilver PTX Drug-Eluting Peripheral StentP100022/S045 | Cook Ireland, Ltd. | PMA supplement | Mar 25, 2026 | FDA |
| Cook Ireland, Ltd. | PMA approval | Nov 14, 2012 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- One Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P180011/S067
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


